Adam Feuerstein on Muck Rack

Adam Feuerstein

As seen in: The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Merck Potential Blockbuster Drug, Key Acquisition Make It a Good Bet for Investors — To ensure that you have a comfortable retirement, you need to find those investments that are guaranteed to generate a steady stream of profits -- not just for the next 12 months, but long term. One way to find them is to focus on those making the most progress in battling chronic diseases.

Bristol-Myers Squibb Stock Will Bounce Back -- Here's How You Can Profit — Bristol-Myers Squibb ( BMY) shares have taken a beating recently, but the heavy selling appears to be over, and now traders should consider how to profit from a recovery in the stock's price. On Aug. 5, the stock plummeted 16% to $63.28 on news that the company's Opdivo immunotherapy drug failed a clinical trial for its use as an initial treatment for lung cancer.

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism — Shares of biotech micro-cap Cyclacel Pharmaceuticals ( CYCC) have doubled in price in the past ten days. Call it the Lloyd Christmas effect. Dumb & Dumber. You can sort of understand why momentum traders would be attracted to a penny biotech stock like Cyclacel.

3 ETFs to Play Biotech's Bounce Back From Disaster — The adage "There's no such thing as bad press" is a lot of malarkey (to use a word favored by Vice President Joe Biden). That's especially true when it comes to the volatile biotechnology sector, which relies on the goodwill of regulators, politicians and the public. For biotech stocks, bad press is a killer.

Pfizer Nears $14B Takeover of Cancer Drug Maker Medivation — Medivation ( MDVN) CEO David Hung has once again delivered big-time value for shareholders as Pfizer ( PFE) is said to be finalizing a deal to buy the cancer drug maker for $14 billion. The finalized deal could be announced Monday morning, according to the Financial Times, citing sources familiar with negotiations between the two companies.

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta — August is slow and I'll be on vacation all next week, so I'm using this week's Biotech Stock Mailbag to tie up some loose ends. Tobin R. asks, "Heron Therapeutics (HRTX) got approval for Sustol [Wednesday] and it looks good, as they were able to make the label include the benefit for stopping delayed-onset nausea and vomiting in patients undergoing highly emetogenic chemotherapy.

Short of Cash, Northwest Bio Flirts With Insolvency — Is Northwest Biotherapeutics ( NWBO) financially insolvent? The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses, according to the latest quarterly report filed with the Securities and Exchange Commission. Northwest Bio did not respond to questions about its financial health.

Sarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines' — NEW YORK ( TheStreet) -- Shares of Sarepta Therapeutics (SRPT) were retreating mid-Wednesday morning as speculation mounts that the company's Duchenne muscular dystrophy therapy eteplirsen could get a "differing-professional-opinions" proceeding by the FDA.

Biotech Stock Mailbag: Ionis, Trust Issues and 'Oops! Don't Look at That Slide Deck' — Kynamro managed to win a positive recommendation from the advisory panel and the FDA later approved the drug, but the disclosure of safety problems caused permanent damage. Kynamro was a commercial flop.

Bristol-Myers Plunges on Shocking Cancer Immunotherapy Lung Cancer Study Failure — A cancer immunotherapy shocker has Bristol-Myers Squibb ( BMY) tumbling and rival Merck ( MRK) soaring on Friday morning. Bristol's blockbuster checkpoint inhibitor Opdivo failed to meet the primary endpoint in a very important phase III clinical trial involving patients with newly diagnosed non-small cell lung cancer, the company announced.
More Articles →
Aug 24, 2016

@McMenaminTK The EpiPen price increases are not fiction. They’re fact. $MYL

Aug 24, 2016

Fox Business is hammering $MYL for EpiPen. Fox Business.

Aug 24, 2016

$AMGN — FDA rejected Parsabiv, for 2ndary hyperparathyroidism.

Aug 24, 2016

I guess I should just ask you, @JimGreenwood — Is there any drug price or pricing strategy that you find objectionable or unsustainable?

Aug 24, 2016

Is there any drug-price increase that @JimGreenwood & his crew find objectionable? If the answer is no, biotech is in heap of trouble.

Aug 24, 2016

Boston beer fans — @BoneUpBrewing tap room grand opening on Saturday. Right down the street from @NightShiftBeer. Visit both!

Are You a Journalist?

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Create a Portfolio